Attovia Therapeutics, Inc. (ATTO)

Attovia Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Revenue Revenue Growth	1.35	1.35	-
Revenue Growth	-	-	-
Gross Profit Gross Profit Growth	-57.61	-52.8	-33.86
Operating Income Operating Income Growth	-71.01	-67.16	-41.55
Net Income Net Income Growth	-64.13	-60.63	-39.8
Earnings Per Share EPS Growth	-15.89	-15.35	-11.27
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	132.62	152.27	69.32
Total Debt Total Debt Growth	4.8	5.26	-
Net Cash (Debt) Net Cash Growth	127.82	147.01	69.32
Net Cash Growth	-	112.06%	-
Net Cash Per Share Net Cash Per Share Growth	31.67	37.22	19.63

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-63.21	-59.2	-35.04
Capital Expenditures CapEx Growth	-0.81	-2.31	-1.77
Free Cash Flow Free Cash Flow Growth	-64.02	-61.51	-36.81
Free Cash Flow Growth	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Operating Margin	-5260.00%	-4974.74%	-
Pretax Margin	-4750.52%	-4490.89%	-
Profit Margin	-4750.52%	-4490.89%	-
FCF Margin	-4742.07%	-4556.44%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error